Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Systemic Sclerosis Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Systemic Sclerosis Drug Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 ARG-201
      • 1.3.3 Belimumab
      • 1.3.4 BL-1110
      • 1.3.5 BOT-191
      • 1.3.6 C-82
      • 1.3.7 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Systemic Sclerosis Drug Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
      • 1.4.4 ASCs
      • 1.4.5 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Systemic Sclerosis Drug Market Size
      • 2.1.1 Global Systemic Sclerosis Drug Revenue 2014-2025
      • 2.1.2 Global Systemic Sclerosis Drug Sales 2014-2025
    • 2.2 Systemic Sclerosis Drug Growth Rate by Regions
      • 2.2.1 Global Systemic Sclerosis Drug Sales by Regions 2014-2019
      • 2.2.2 Global Systemic Sclerosis Drug Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Systemic Sclerosis Drug Sales by Manufacturers
      • 3.1.1 Systemic Sclerosis Drug Sales by Manufacturers 2014-2019
      • 3.1.2 Systemic Sclerosis Drug Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Systemic Sclerosis Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Systemic Sclerosis Drug Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Systemic Sclerosis Drug Market Concentration Ratio (CR5 and HHI)
    • 3.3 Systemic Sclerosis Drug Price by Manufacturers
    • 3.4 Key Manufacturers Systemic Sclerosis Drug Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Systemic Sclerosis Drug Market
    • 3.6 Key Manufacturers Systemic Sclerosis Drug Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 ARG-201 Sales and Revenue (2014-2019)
      • 4.1.2 Belimumab Sales and Revenue (2014-2019)
      • 4.1.3 BL-1110 Sales and Revenue (2014-2019)
      • 4.1.4 BOT-191 Sales and Revenue (2014-2019)
      • 4.1.5 C-82 Sales and Revenue (2014-2019)
      • 4.1.6 Others Sales and Revenue (2014-2019)
    • 4.2 Global Systemic Sclerosis Drug Sales Market Share by Type
    • 4.3 Global Systemic Sclerosis Drug Revenue Market Share by Type
    • 4.4 Systemic Sclerosis Drug Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Systemic Sclerosis Drug Sales by Application

    6 United States

    • 6.1 United States Systemic Sclerosis Drug Breakdown Data by Company
    • 6.2 United States Systemic Sclerosis Drug Breakdown Data by Type
    • 6.3 United States Systemic Sclerosis Drug Breakdown Data by Application

    7 European Union

    • 7.1 European Union Systemic Sclerosis Drug Breakdown Data by Company
    • 7.2 European Union Systemic Sclerosis Drug Breakdown Data by Type
    • 7.3 European Union Systemic Sclerosis Drug Breakdown Data by Application

    8 China

    • 8.1 China Systemic Sclerosis Drug Breakdown Data by Company
    • 8.2 China Systemic Sclerosis Drug Breakdown Data by Type
    • 8.3 China Systemic Sclerosis Drug Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Systemic Sclerosis Drug Breakdown Data by Company
    • 9.2 Rest of World Systemic Sclerosis Drug Breakdown Data by Type
    • 9.3 Rest of World Systemic Sclerosis Drug Breakdown Data by Application
    • 9.4 Rest of World Systemic Sclerosis Drug Breakdown Data by Countries
      • 9.4.1 Rest of World Systemic Sclerosis Drug Sales by Countries
      • 9.4.2 Rest of World Systemic Sclerosis Drug Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Allergan Plc
      • 10.1.1 Allergan Plc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.1.4 Systemic Sclerosis Drug Product Introduction
      • 10.1.5 Allergan Plc Recent Development
    • 10.2 Angion Biomedica Corp.
      • 10.2.1 Angion Biomedica Corp. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.2.4 Systemic Sclerosis Drug Product Introduction
      • 10.2.5 Angion Biomedica Corp. Recent Development
    • 10.3 arGentis Pharmaceuticals, LLC
      • 10.3.1 arGentis Pharmaceuticals, LLC Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.3.4 Systemic Sclerosis Drug Product Introduction
      • 10.3.5 arGentis Pharmaceuticals, LLC Recent Development
    • 10.4 Bayer AG
      • 10.4.1 Bayer AG Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.4.4 Systemic Sclerosis Drug Product Introduction
      • 10.4.5 Bayer AG Recent Development
    • 10.5 BioLineRx, Ltd.
      • 10.5.1 BioLineRx, Ltd. Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.5.4 Systemic Sclerosis Drug Product Introduction
      • 10.5.5 BioLineRx, Ltd. Recent Development
    • 10.6 BiOrion Technologies B.V.
      • 10.6.1 BiOrion Technologies B.V. Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.6.4 Systemic Sclerosis Drug Product Introduction
      • 10.6.5 BiOrion Technologies B.V. Recent Development
    • 10.7 Boehringer Ingelheim GmbH
      • 10.7.1 Boehringer Ingelheim GmbH Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.7.4 Systemic Sclerosis Drug Product Introduction
      • 10.7.5 Boehringer Ingelheim GmbH Recent Development
    • 10.8 Bristol-Myers Squibb Company
      • 10.8.1 Bristol-Myers Squibb Company Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.8.4 Systemic Sclerosis Drug Product Introduction
      • 10.8.5 Bristol-Myers Squibb Company Recent Development
    • 10.9 Corbus pharmaceuticals, Inc.
      • 10.9.1 Corbus pharmaceuticals, Inc. Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.9.4 Systemic Sclerosis Drug Product Introduction
      • 10.9.5 Corbus pharmaceuticals, Inc. Recent Development
    • 10.10 CSL Limited
      • 10.10.1 CSL Limited Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Systemic Sclerosis Drug
      • 10.10.4 Systemic Sclerosis Drug Product Introduction
      • 10.10.5 CSL Limited Recent Development
    • 10.11 Daval International Limited
    • 10.12 Digna Biotech, S.L.
    • 10.13 F. Hoffmann-La Roche Ltd.
    • 10.14 Fibrocell Science, Inc.
    • 10.15 GenKyoTex S.A.
    • 10.16 GlaxoSmithKline Plc

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Systemic Sclerosis Drug Sales Channels
      • 11.2.2 Systemic Sclerosis Drug Distributors
    • 11.3 Systemic Sclerosis Drug Customers

    12 Market Forecast

    • 12.1 Global Systemic Sclerosis Drug Sales and Revenue Forecast 2019-2025
    • 12.2 Global Systemic Sclerosis Drug Sales Forecast by Type
    • 12.3 Global Systemic Sclerosis Drug Sales Forecast by Application
    • 12.4 Systemic Sclerosis Drug Forecast by Regions
      • 12.4.1 Global Systemic Sclerosis Drug Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Systemic Sclerosis Drug Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Systemic Sclerosis Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Systemic Sclerosis Drug.

      This report studies the global market size of Systemic Sclerosis Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Systemic Sclerosis Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Allergan Plc
      Angion Biomedica Corp.
      arGentis Pharmaceuticals, LLC
      Bayer AG
      BioLineRx, Ltd.
      BiOrion Technologies B.V.
      Boehringer Ingelheim GmbH
      Bristol-Myers Squibb Company
      Corbus pharmaceuticals, Inc.
      CSL Limited
      Daval International Limited
      Digna Biotech, S.L.
      F. Hoffmann-La Roche Ltd.
      Fibrocell Science, Inc.
      GenKyoTex S.A.
      GlaxoSmithKline Plc

      Market Segment by Product Type
      ARG-201
      Belimumab
      BL-1110
      BOT-191
      C-82
      Others

      Market Segment by Application
      Hospital
      Clinic
      ASCs
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Systemic Sclerosis Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Systemic Sclerosis Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Systemic Sclerosis Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now